$PMI

Philip Morris set a quarterly revenue record at $11.4 billion as reported earnings per share fell 4.9%.

Philip Morris International (PMI) reported Q3 2026 revenue of $11.4B, up from prior year, with EPS down 4.9%. Shipments rose, driven by smoke-free products like IQOS. Combustibles segment showed resilience. PMI raised its quarterly dividend and expects continued growth.

Original reporting
Published Oct 21, 2026, 10:59 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 11:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$PMI
Neutral
high confidence
Mentioned
$PMI
Relevance
8/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$PMINeutralMed
01

Why it matters

The earnings release provides fresh data that could affect PMI's stock price and sector sentiment.

02

Market read

PMI's earnings are a primary market-moving event for the tobacco sector and can influence consumer discretionary sentiment.

03

What to watch

Regulatory developments on smoke‑free products and upcoming FDA decisions could drive future upside.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

Philip Morris International released its Q3 2026 earnings, highlighting record revenue and a decline in EPS.

Company-level read

Ticker impact

$PMINeutralHigh confidence
Context

Q3 2026 results show record quarterly revenue of $11.4B but EPS fell 4.9%, indicating mixed performance.

Expected impact

likely modest downside as investors weigh earnings miss against revenue record

Evidence & confidence

The earnings release provides new numbers; revenue strength is positive but EPS miss suggests margin pressure, leading to potential short-term sell pressure.

Market effects

Tobacco sector may see mixed reactions; strong smoke‑free growth offsets combustible weakness.

European and Asian markets could react to PMI's regional performance updates.

PMI is a major global tobacco player; its earnings influence broader consumer discretionary sentiment.

Counterpoint

Investors might focus on the record revenue and view the EPS miss as a temporary issue.

Key entities

  • Philip Morris International Inc.

    Global tobacco company reporting Q3 2026 results.

  • Jacek Olczak

    Group CEO of PMI who commented on the quarter.

Related articles

$PMIHighAI 8/10

Picard Medical stock rises 27% as Q2 revenue nearly doubles estimate

Picard Medical Inc. (PMI) shares rose 27% after Q2 2026 revenue of $2.954M beat estimates by 90.58%, up 38.62% YoY. Despite a loss of $(3.05) per share, investors focused on top-line growth and improved gross margins. The company is investing in R&D for its next-gen Emperor Total Artificial Heart, presenting new data at conferences. PMI completed a 1-for-50 reverse stock split in July 2026 to regain NYSE compliance.

$PMIMed

Biotech Gainers: PMI Revenue Growth, SDOT Earnings Surge, CAPR FDA Update, GRI Data Drive Gains

Picard Medical (PMI) rose 40% after reporting Q2 revenue growth of 39% to $3.0M. Sadot Group (SDOT) surged 100% despite zero revenue, with net income up to $35.2M. Capricor Therapeutics (CAPR) gained 11% after FDA extended review for deramiocel. GRI Bio (GRI) climbed 10% with Phase 2a data selected for ERS 2026. Biomea Fusion (BMEA) rose 14% after completing Phase 2 diabetes trial enrollment. Yarrow Bioscience (YARW) advanced 12% with Graves' disease trial updates.

$PMIMedAI 8/10

PMI revenues top $11bn as IQOS grows share in Global Travel Retail

Philip Morris International reported Q2 2026 net revenues of $11.2bn, up 10.4% year on year and 7.6% organically. Gross profit rose to $7.7bn and operating income to $4.5bn. Smoke-free shipments increased 7.5%, with IQOS holding a 21.5% Global Travel Retail airport offtake share (Mar-May). PMI plans $1.4bn-$1.6bn capex for 2026.

$BJDXMedAI 9/10

Top Biotech Gainers: PMI Advances Artificial Heart, CUE Makes Board Changes, CING Up Despite CRL

Healthcare stocks rose Tuesday on multiple biotech updates. Bluejay Diagnostics (BJDX) surged 100% after a strategic partnership with Argonaut to advance its Symphony diagnostic platform and announced a private placement up to $23.6M. Picard Medical (PMI) gained 60.33% after completing animal implant studies of its Emperor total artificial heart. Legend Biotech (LEGN) rose 42.22% ahead of EHA Phase 1 data. CUE climbed 18.93% with board changes. Cingulate (CING) rose 11.94% despite the FDA declin

$BJDXMedAI 9/10

Top Biotech Gainers: PMI Advances Artificial Heart, CUE Makes Board Changes, CING Up Despite CRL

Healthcare biotech gainers on Tuesday included Bluejay Diagnostics (BJDX), which said it signed a strategic partnership with Argonaut to support its Symphony near-patient diagnostic platform; BJDX shares rose 100% to $4.34 and the company also announced a private placement up to $23.6M. Picard Medical (PMI) reported completed animal implant studies for its next-gen Emperor total artificial heart; shares rose 60.33% to $0.27. Legend Biotech (LEGN) said it will present Phase 1 data for LB2501 show